{
    "nct_id": "NCT06001658",
    "official_title": "Tumor Microenvironment Features of Response to Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers",
    "inclusion_criteria": "* Must have a newly diagnosed, biopsy-proven biliary tract cancer (BTC) including gallbladder, intrahepatic, extrahepatic, and hilar cholangiocarcinoma.\n* Resectable BTC (biliary tract cancer)\n* Measurable disease per RECIST 1.1 as determined by the investigator.\n* Age ≥18 years.\n* ECOG (Eastern Cooperative Oncology Group) performance status ≤1 or Karnofsky ≥80\n* Patients must have adequate organ and marrow function defined by study-specified laboratory tests.\n* Patients must have adequate liver function defined by study-specified laboratory tests.\n* Patients with chronic or acute HBV or HCV infection must have disease controlled prior to enrollment.\n* Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test.\n* For both Women and Men, must use acceptable form of birth control while on study.\n* Ability to understand and willingness to sign a written informed consent document.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Receiving, or previously received, any systemic chemotherapy, or investigational agent for BTC.\n* Has received prior radiotherapy within 2 weeks of start of study intervention.\n* Patients with a history of prior treatment with anti-PD-1 and anti-PD-L1.\n* Have been diagnosed with another cancer or myeloproliferative disorder whose natural history or treatment has the potential to interfere with safety or efficacy assessment of this study's investigational drugs.\n* Has a known history of Human Immunodeficiency Virus (HIV)/AIDS\n* Has active co-infection with HBV and HDV.\n* Has a diagnosis of immunodeficiency.\n* Has active autoimmune disease that has required systemic treatment in the past 2 years.\n* Systemic or topical corticosteroids at immunosuppressive doses.\n* Prior allogeneic stem cell transplantation or organ transplantation.\n* Prior tissue or organ allograft or allogeneic bone marrow transplantation, including corneal transplants.\n* Uncontrolled intercurrent active medical and/or psychiatric illness/social psychosocial problems that that would limit compliance with study requirements.\n* Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Evidence of clinical ascites.\n* Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.\n* Previously identified allergy or hypersensitivity to monoclonal antibodies or any component of the study treatment formulations.\n* Pregnant or breastfeeding.\n* WOCBP and men with female partners (WOCBP) who are not willing to use contraception.\n* Subjects unable to undergo venipuncture and/or tolerate venous access.\n* Patient is at the time of signing informed consent a regular user (including \"recreational use\") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol).",
    "miscellaneous_criteria": ""
}